A Follower In Home Healthcare Sent Us This $1.5 Million Deal To Reviewsmart_display

One of our followers who works in the home healthcare industry sent us this listing and asked us to review the deal.

The business provides in-home physical therapy, occupational therapy, and speech therapy services, primarily helping patients remain independent and receive treatment in their own homes.

According to the listing, the company generates more than $2.2 million in annual revenue and approximately $410,000 in seller's discretionary earnings.

The company also reportedly has more than 27 years of operating history, a loyal patient base, recurring revenue, and an established reputation.

Those qualities could make this a valuable healthcare-services platform. But the listing provides very little detail about the payer mix, patient-acquisition channels, referral concentration, staffing model, reimbursement rates, or compliance history.

Deal Snapshot

The Business Remains Solidly Cash Flow Positive After Debt

Using the calculator's acquisition assumptions with 10% down, the business is projected to leave the buyer with approximately $187,794 per year after loan payments.

SBA Financing Scenario

A DSCR of 1.90 means the company produces approximately 1.9 times the cash flow required to cover its annual debt payments.

That gives the buyer a comfortable cushion above the loan obligation and leaves nearly $188,000 before taxes, future reinvestment, and any additional management or staffing expenses.

The financing works on the reported numbers. The central question is whether those earnings remain stable after ownership changes and whether they justify the premium purchase price.

The Valuation Is Well Above The Industry Average

The asking price equals approximately 3.66x cash flow, compared with an industry average of roughly 2.67x.

That means the buyer is paying nearly one full additional turn of cash flow above the broader home healthcare benchmark.

The revenue multiple is also elevated. The business is priced at approximately 0.68x revenue, compared with an industry average closer to 0.54x.

A premium valuation can be justified by superior margins, predictable referrals, attractive contracts, strong clinical leadership, low patient concentration, or a durable reimbursement structure.

But the listing does not provide enough information to confirm that those advantages exist.

The Margin Is Slightly Below The Benchmark

The company reports an 18.64% profit margin, compared with an industry average of approximately 20.16%.

That is not a major weakness by itself, particularly in a labor-intensive healthcare business.

However, it does make the premium valuation harder to explain.

A buyer paying substantially more than the average cash-flow multiple would normally want to see above-average margins, unusually predictable revenue, strong organic growth, or a clear strategic advantage.

The company may possess those qualities, but the listing relies more heavily on marketing language than supporting operating data.

What Looks Attractive

• Strong post-debt cash flow: The buyer is projected to retain approximately $187,794 annually after loan payments.
• Comfortable debt coverage: A 1.90 DSCR provides a meaningful cushion above annual debt obligations.
• Long operating history: More than 27 years in business suggests established processes, relationships, and market credibility.
• Recurring patient demand: Ongoing therapy needs may create repeated visits and relatively predictable revenue.
• Broad service offering: Physical, occupational, and speech therapy allow the company to serve multiple patient needs.
• Aging-population demand: More patients and families are seeking ways to safely receive care at home.
• Reputation and experience: A long-standing provider may benefit from trust among patients, physicians, facilities, and referral partners.
• Potential platform value: An established clinical and administrative operation could support geographic or service-line expansion.

The Listing Makes Big Claims

The marketing describes the company as a cash-flow powerhouse, highlights massive demographic tailwinds, and states that demand is exploding.

Those claims may be directionally correct. The population is aging, many patients prefer receiving treatment at home, and home-based care can reduce transportation and accessibility challenges.

But broad industry demand does not automatically make one specific business a strong acquisition.

A buyer still needs to verify historical patient volume, revenue growth, referral trends, reimbursement changes, clinician productivity, cancellation rates, patient retention, and profitability by service line.

Before paying a premium multiple, the buyer should replace every marketing claim with measurable operating evidence.

Referral Concentration Could Completely Change The Risk

Healthcare businesses often depend on referral relationships rather than ordinary consumer marketing.

Patients may be referred by physicians, hospitals, rehabilitation facilities, skilled nursing facilities, assisted-living communities, case managers, home health agencies, insurance networks, or other healthcare professionals.

A company can appear diversified because it treats many patients while still depending heavily on only a few organizations that supply those patients.

If one hospital system, physician group, facility, or referral coordinator accounts for a meaningful percentage of new patients, losing that relationship could materially reduce revenue.

The buyer should therefore analyze referrals by source, location, clinician, service line, and month.

It is also important to determine whether those relationships belong to the organization or are personally tied to the seller, a clinical director, or another key employee.

Payer Mix May Be The Most Important Financial Detail

The listing does not disclose how the company is paid.

Revenue may come from Medicare, Medicare Advantage plans, Medicaid, commercial insurance, workers' compensation, private pay, contracted facilities, or a combination of sources.

Each payer type has different reimbursement rates, authorization requirements, documentation standards, payment timing, denial risk, and collection expense.

A company with diversified payers and favorable reimbursement contracts may deserve a premium.

A company heavily dependent on one government program, insurer, or contract may face greater reimbursement and concentration risk.

The buyer should review revenue, gross margin, denial rates, days in accounts receivable, write-offs, and reimbursement trends by payer.

Recurring Revenue Needs A Clear Definition

The listing promotes recurring revenue and a loyal patient base, but recurring healthcare revenue can mean several different things.

A patient may receive multiple scheduled therapy visits during an episode of care, creating repeat revenue for several weeks or months.

However, that does not necessarily mean the revenue is contractually recurring or predictable indefinitely.

Patient episodes may end when goals are met, authorization expires, insurance limits are reached, the patient is discharged, or the patient's medical condition changes.

The buyer should measure average visits per patient, average revenue per episode, patient retention, referral frequency, reauthorization rates, and the percentage of revenue tied to standing facility or network relationships.

True contractual or referral-driven repeatability would support the premium valuation more strongly than temporary repeat visits within individual care episodes.

Clinical Staffing Is Another Critical Risk

Physical therapists, occupational therapists, and speech-language pathologists are licensed professionals.

The company's ability to generate revenue depends on recruiting, credentialing, scheduling, and retaining enough qualified clinicians to serve patients.

The buyer should understand whether clinicians are employees or independent contractors, how they are compensated, how productive they are, and how much turnover the business experiences.

Travel time between patients can also materially affect profitability. A clinician may appear productive based on completed visits while losing significant paid or unpaid time driving across a large service territory.

If the company must increase wages, reimburse mileage, add recruiting staff, or hire clinical leadership after closing, normalized cash flow may be lower than the reported SDE.

Potential Risks

• Premium valuation: The 3.66x cash-flow multiple is significantly above the industry average of approximately 2.67x.
• Referral concentration: Revenue may depend on a limited number of hospitals, physicians, facilities, or care coordinators.
• Payer concentration: Heavy reliance on Medicare, one insurer, or a small number of reimbursement contracts could create financial risk.
• Reimbursement pressure: Rate reductions, authorization changes, denials, and delayed payments can materially affect cash flow.
• Clinician availability: Licensed therapists may be difficult or expensive to recruit and retain.
• Owner or clinical-director dependence: Key referral, compliance, credentialing, or operational responsibilities may be concentrated in one person.
• Compliance exposure: Documentation, billing, coding, patient privacy, and medical-necessity requirements create audit and recoupment risk.
• Unclear recurring revenue: Repeat visits during short-term episodes of care may be less durable than long-term contracts.
• Travel inefficiency: In-home care can produce excessive clinician drive time and weaker utilization.
• Limited listing detail: The marketing materials provide few concrete facts about employees, contracts, facilities, growth, or the reason for sale.

The First Questions I Would Ask

Where does every patient come from?

I would request at least three years of referral data showing patients and revenue by physician, facility, hospital, agency, insurer, geographic market, and other referral source.

I would also ask what percentage of revenue comes from Medicare, Medicare Advantage, Medicaid, commercial insurance, private pay, facility contracts, and other sources.

The buyer should identify the largest payer, the largest referral source, the largest facility relationship, and the percentage of total revenue represented by each.

I would then determine whether those relationships are contractual, informal, transferable, or personally tied to the current owner or a key employee.

Finally, I would ask why the business is being sold, since the listing does not disclose the seller's motivation.

The Financials Need Healthcare-Specific Verification

Standard tax returns and profit-and-loss statements are not enough to evaluate a healthcare-services company.

The buyer should review patient census, visits completed, visits authorized, visits denied, average reimbursement per visit, clinician compensation per visit, gross margin by discipline, and accounts-receivable aging.

Revenue should be analyzed separately for physical therapy, occupational therapy, and speech therapy.

The buyer should also reconcile billed revenue, allowed amounts, payments received, contractual adjustments, denials, refunds, write-offs, and any outstanding recoupment exposure.

Monthly data can reveal whether reported growth comes from higher patient volume, additional visits per patient, improved reimbursement, acquisitions, new referral sources, or temporary changes in billing.

Compliance Diligence Is Essential

Healthcare acquisitions carry regulatory and billing risks that may not be visible in the headline financials.

The buyer should review clinician licenses, payer credentials, patient documentation, billing procedures, coding practices, privacy policies, quality controls, complaints, audits, repayment demands, and any history of regulatory investigations.

Any prior Medicare, Medicaid, insurer, or contractor audits should be examined carefully, including findings, corrective actions, overpayments, and unresolved appeals.

The buyer should also verify whether payer contracts and provider enrollments transfer after a change of ownership or require new applications and approvals.

A delay in credentialing or reimbursement approval could interrupt billing after closing even if patient demand remains strong.

What Could Justify The Premium?

The 3.66x multiple may still be reasonable if diligence confirms several advantages.

A diversified referral base, favorable payer contracts, low clinician turnover, strong organic growth, clean compliance history, efficient route density, and limited owner dependence would materially improve the deal.

The company's 27-year history could also support the valuation if revenue and earnings have remained stable across reimbursement changes and economic cycles.

The strongest version of this deal would be an established clinical platform with durable institutional referrals, transferable payer relationships, experienced management, and consistent patient demand.

Without those qualities, the buyer may simply be paying above-average pricing for an average-margin healthcare business.

What I Would Verify During Diligence

I would request tax returns, monthly financial statements, detailed accounts-receivable aging, payer remittance reports, clinician payroll, contractor payments, patient census data, referral reports, credentialing records, payer contracts, compliance policies, audit history, and licenses.

The buyer should calculate revenue, gross margin, denial rates, collection timing, and profitability by payer, service line, clinician, referral source, and geographic area.

Employee and contractor turnover, wage trends, clinician productivity, unfilled positions, drive time, mileage costs, and open patient demand should also be reviewed.

Any management, clinical-director, billing, credentialing, compliance, or referral-development responsibilities currently performed by the seller should be assigned a realistic replacement cost.

Most importantly, the buyer should determine whether the company's recurring revenue and referral pipeline are truly as durable as the listing suggests.

BizHub Verdict

BizHub scores this deal a 6.5 / 10.

The company has a long operating history, positive post-debt cash flow, a comfortable 1.90 DSCR, and exposure to growing demand for in-home therapy services.

It could absolutely be a high-quality healthcare business and potentially a valuable platform for expansion.

However, the 3.66x cash-flow multiple is well above the industry average, while the reported margin is slightly below the benchmark.

The listing also provides limited information about payer mix, referral concentration, clinician retention, contracts, compliance, and ownership dependence.

Before paying a premium multiple, I would want to verify that the recurring revenue, reimbursement profile, and referral pipeline are just as strong as the marketing makes them sound.

Want to pressure test deals like this yourself? Try the BizHub Deal Calculator →

Read more at the original source →